Congress admits biosafety gaps

This in from news editor Alla Katsnelson: At a congressional hearing on linkurl:biosafety;http://www.the-scientist.com/news/display/53626/ today (October 4), the Government Accountability Office reported that the federal government doesn't know how many labs are involved in biosafety level 3 and level 4 work, or where those labs are. Although labs working with certain "select agents" are under the oversight of the CDC, labs working with other pathogens such as SARS or Hantavirus a

Written byAlison McCook
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
This in from news editor Alla Katsnelson: At a congressional hearing on linkurl:biosafety;http://www.the-scientist.com/news/display/53626/ today (October 4), the Government Accountability Office reported that the federal government doesn't know how many labs are involved in biosafety level 3 and level 4 work, or where those labs are. Although labs working with certain "select agents" are under the oversight of the CDC, labs working with other pathogens such as SARS or Hantavirus are not required to report mishaps. "No single federal agency, according to 12 agencies' response to our survey, has the mission to track the overall numbers of BSL3 and BSL4 labs in the United States," the GAO wrote in linkurl:testimony;http://energycommerce.house.gov/cmte_mtgs/110-oi-hrg.100407.BSL.shtml submitted to the hearing. "Consequently, no agency is responsible for determining the risks associated with the proliferation of these labs. " The GAO's report counted 17 federal agencies funding BSL3 or BSL4 research.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies